Thursday, May 14, 2020

Calliditas Therapeutics: Interim Report Q1, 2020

STOCKHOLM, May 14, 2020 /PRNewswire/ -- "In the end of the first quarter of 2020 much of the activity at the company was focused on assessing and mitigating any potential impact Covid-19 might have on NefIgArd and I am happy to report that, due to the fact that the Part A of the study was...



from PR Newswire: https://ift.tt/2T2TkDv

No comments:

Post a Comment